Navigation Links
Cancer Drug Gleevec Could Fight Stroke
Date:6/23/2008

It might extend the effectiveness of clot-busting tPA, researchers say

MONDAY, June 23 (HealthDay News) -- A powerful weapon against cancer might also boost stroke patients' survival, new research suggests.

Gleevec, long hailed as a "wonder drug" against cancers such as chronic myelogenous leukemia (CML), will be tested to see if it can boost the effectiveness and limit the side effects of the clot-dissolving drug tissue plasminogen activator (tPA), an international team of researchers say.

One of the ways that Gleevec stops the growth of cancer cells is to block receptors of platelet-derived growth factor-CC (PDGF-CC), explained Daniel Lawrence, professor of cardiovascular medicine at the University of Michigan and a member of the research team.

Studies performed at his lab, as well as at Sweden's Karolinska Institute, have both shown that blocking those receptors improves the activity of tPA.

Doctors typically give tPA in the hours after an ischemic stroke, which occurs when a blood clot blocks a brain artery. About 80 percent of all strokes are ischemic, and tPA is given to dissolve the clots.

But there's a big downside with the drug: It also can increase the odds for brain hemorrhage.

Reporting in the June 22 online edition of the journal Nature Medicine, the researchers at Karolinska and in Michigan showed for the first time that tPA increases the risk of bleeding by acting on PDGF-CC, as well as the cellular receptor to which it binds. This activity makes blood vessels in the brain dangerously leaky.

However, in other laboratory tests and in animal studies, Gleevec prevented this leakiness by blocking PDGF-CC receptors.

"Blocking the receptor reduces formation of edema -- swelling of the brain -- and so even in the absence of tPA, the [Gleevec] treatment would be beneficial," Lawrence pointed out.

But Gleevec might also extend tPA's usefulness, he added. "tPA loses its efficacy three hours after a stroke. Part of that loss may be an increase in major side effects, and the major side effect of tPA is bleeding," Lawrence explained. "You could conceivably block the receptor and give tPA beyond its current three-hour limit and still be effective at removing the blockage of a brain artery but reduce the complications."

Gleevec is not necessarily the perfect drug to achieve that effect, Lawrence said, because its activity on a number of other receptors could raise new concerns. "We are not currently testing any [other drug] in our laboratory, but any drug that blocks those receptors might possibly be even better than Gleevec," he said. "One could develop even more specific receptor blockers."

A first human trial, primarily to test the safety of the proposed treatment, will soon begin in Sweden, said Ulf Eriksson, professor of molecular biology at the Karolinska Institute, one of the leaders of the research effort. It will be done by physicians at the Karolinska Institute Hospital in Stockholm.

The trial is planned to include 60 people who will be treated in the hours after they suffer strokes. Some will be given Gleevec within three hours of the stroke in addition to standard tPA treatment. Others whose treatment started later for one reason or another will be given Gleevec in addition to tPA after the three-hour period desired for such treatment. Their results will be compared to similar stroke patients given standard treatment.

Results of that study should be available "within one year," Eriksson said. Plans for future human trials would depend on those results, he said.

More information

There's more on tPA and other stroke therapies at the American Heart Association.



SOURCES: Daniel Lawrence, Ph.D., professor, cardiovascular medicine, University of Michigan, Ann Arbor; Ulf Eriksson, Ph.D., professor, molecular biology, Karolinska Institute, Stockhold, Sweden; June, 22, 2008, online edition, Nature Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Symptoms Plus Blood Test Boost Ovarian Cancer Detection
2. Symptom screening plus a simple blood test improves early detection of ovarian cancer
3. Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis
4. Honor a Loved One at The American Cancer Societys Relay for Life
5. Damon Runyon Cancer Research Foundation awards $2.25M to 5 top young clinical investigators
6. CT Screens for Lung Cancer Not a Cure-All
7. Pro Baseball Helps Keep Skin Cancer From Scoring
8. Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Irelands First Nationwide Cervical-Cancer Screening Program
9. American Academy of Dermatology, Major League Baseball and Major League Baseball Players Association Play Sun Smart(TM) to Strike Out Skin Cancer
10. Lack of CHFR gene expression sets stage for breast cancer
11. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Drug Gleevec Could Fight Stroke
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine recently queried ... counties for 2017. Almost 1,000 nominations were submitted and a little over 500 ... were announced the magazine’s January 2017 issue . , Under the category ...
(Date:1/15/2017)... NJ (PRWEB) , ... January 15, 2017 , ... ... firm located in Montclair, NJ is pleased to announce that it will be ... is located in Montclair and Glen Ridge townships, servicing all surrounding towns. The ...
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... AgileMinder develops ... , The Emoji Scale is now available on Apple as a fun, free ... ratings simply by choosing one of the ten color coded values on The Emoji ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... The 18th ... Avenida America hotel on March 3-4, 2017. This Congress is expertly designed to ... the management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, ...
(Date:1/13/2017)... ... January 13, 2017 , ... With the increasing public ... of providing additional organic alternatives for customers who have grown more conscious about ... line of all-natural activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , Jan. 16, 2017  Today, Analytics 4 Life ... devices, announced its expansion into JLABS @ ... life science incubators. As a resident in the space, ... medical device development and commercialization expertise. JLABS ... science innovation center that provides a flexible environment for ...
(Date:1/15/2017)... , January 16, 2017 Der ... Kollagenprodukten für die Regeneration des menschlichen Gewebes, gibt die ... mit sofortiger Wirkung bekannt. ... Bill Allan ... Er bekleidete eine Reihe von Geschäftsführer- und anderen Führungspositionen ...
(Date:1/13/2017)... 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), ... Finance and Investment Banking at Eli Lilly & Company, has ... Bott brings over 28 years of senior financial and executive ... ... has established a significant leadership position in financial and business ...
Breaking Medicine Technology: